Immutep (ASX:IMM) will present new clinical results from its AIPAC-003 Phase 2 trial at next week’s San Antonio Breast Cancer Symposium, highlighting encouraging response rates and clear signs of immune activation in heavily pretreated metastatic breast cancer patients. …
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 Australian Biotech
Latest Video
New Stories
-
First patient successfully dosed in TRP-8803 trial to treat binge eating disorder
December 2, 2025 - - Australian Biotech -
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 - - Australian Biotech -
US and UK strike landmark pharmaceutical deal, lifting prices
December 2, 2025 - - Latest News -
Cartherics appoints Dr Ian Nisbet as CEO as the company accelerates toward clinical trials
December 1, 2025 - - Australian Biotech -
Novo Nordisk appoints Michael Azrak as new Oceania General Manager
December 1, 2025 - - Latest News -
New PBS listing brings immunotherapy option to Australians with rare head and neck cancer
December 1, 2025 - - Latest News -
DBG Health appoints Matt Zeller to lead Arrotex Pharmaceuticals into its next phase of growth
December 1, 2025 - - Latest News